Page last checked 2026-08-12

Combination · what has actually been studied

Tesamorelin and ipamorelin together

Also written Tesamorelin/ipamorelin, or just Tesamorelin ipamorelin.

No trial has tested tesamorelin and ipamorelin together. This pair is the odd one out here, because tesamorelin is a real approved medicine with a printed label. That label covers one narrow use, says the drug is weight neutral, and describes a 2 mg vial mixed and used the same minute. A multi-day blend vial matches none of it.

Source: The EGRIFTA SV label read 2026-08-12, plus searches of ClinicalTrials.gov and PubMed

FDA label Human trial

What matters first

Tested together: No study found
Tesamorelin: FDA label on its own page
Ipamorelin: Human trial on its own page
Example vial ratio: 10 mg to 5 mg

Has anyone tested the two together?

No study has given Tesamorelin and ipamorelin to the same subjects. Not in people, and not in animals. Two searches were run to check, and both are set out below so you can run them yourself.

Searches run for studies naming both Tesamorelin and Ipamorelin
Searched	Query	Records	Gave both
ClinicalTrials.gov	ipamorelin AND tesamorelin	0	0
PubMed	ipamorelin AND tesamorelin	6	0

Both searches were run on 2026-08-12. The links re-run them live, so a newer study will show up there before it shows up here.

The nearest thing to an answer

The one human test of this kind of pairing used two other molecules. It gave sermorelin (GHRH 1-29) and GHRP-2 — neither of them tesamorelin or ipamorelin. Same two families, different molecules, so read it as a clue about the idea rather than a finding about this pair.

Who took part: 8 volunteers, randomized crossover in healthy men, each man taking all three tests
Amounts given: 1 mcg per kilogram of body weight of each peptide, alone and then together, single injection into a vein
What it found: The pair released more growth hormone than either peptide alone, and no more than the two separate results added up. The authors could not show the two working as a team.
What cuts against it: Tesamorelin is a stronger and longer-acting molecule than the sermorelin used in that test, so the size of the effect does not carry across. What carries across is the shape of the question, which nobody has answered for this pair.

Source: Tiulpakov AN, Brook CG, Pringle PJ, Peterkova VA, Volevodz NN. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clin Endocrinol (Oxf) 1995;43(3):347-50 · retrieved 2026-08-12.

Why these two get paired

Same two-door idea as the other growth hormone pairs. Tesamorelin knocks on the growth hormone releasing door and ipamorelin flips the ghrelin switch. What makes this pair different is that one half is an approved drug and the other has never been injected under the skin in any trial.

What each one was really studied as

Every figure below comes from that compound’s own published sources, with the citation attached. The gap line shows what stack protocols often leave unanswered.

TesamorelinFDA label

An approved growth hormone releasing factor, sold as Egrifta SV and Egrifta WR

Studied as

Its label sets 1.4 mg once a day into the belly, for one use only: cutting excess belly fat in adults with HIV who have lipodystrophy.

Where that stops

The label prints a limitation in its own words — the drug is not for weight loss and its effect on weight is neutral. It also carries a real cost: by week 26, IGF-1 had passed the +2 mark in 47% of people, and HbA1c reached 6.5% or higher in 5% against 1% on a dummy treatment.

The full Tesamorelin record Tesamorelin side effects, sourced

IpamorelinHuman trial

Flips the ghrelin switch on the pituitary, a separate receptor from the one above

Studied as

Two phase 2 trials in 437 people recovering from bowel surgery, at 0.03 to 0.06 mg per kilogram of body weight

Where that stops

Every dose went into a vein, in hospital, set by body weight. The published trial missed its target: people could eat a meal without trouble after 25.3 hours against 32.6 on a dummy treatment, a gap too small to count.

The full Ipamorelin record Ipamorelin side effects, sourced

If it came as one blend vial

Two separate vials are two separate sums, and the per-compound calculators already do those. A blend vial is a different object: both peptides sit in one liquid, so one draw carries both and the ratio was fixed by whoever filled it. The most-searched pairing for these two is 10 mg tesamorelin with 5 mg ipamorelin, so that is the vial the table describes.

What one U-100 unit contains from a 10 mg plus 5 mg blend vial at each mixing volume
Water added	Tesamorelin	Ipamorelin	Per U-100 unit
2 mL	5.00 mg/mL	2.50 mg/mL	50 mcg + 25 mcg
3 mL	3.33 mg/mL	1.67 mg/mL	33 mcg + 17 mcg
5 mL	2.00 mg/mL	1.00 mg/mL	20 mcg + 10 mcg

Deterministic arithmetic: concentration = milligrams divided by water, and one U-100 unit is 0.01 mL. The vial strengths come from our own keyword harvest, where 2x blend tesamorelin 10mg / ipamorelin 5mg dosage draws 110 US searches a month. That is a record of what people look for, not a recommendation.

Set the syringe by one, and see what the other does

This is the part two separate calculators cannot show you. In a blend there is one volume and two peptides, so only one of them can be the number you choose. Pick that one below. The panel on the right reports what arrives with it.

Mixing water10 mg + 5 mg in one vial

Syringe

Set the syringe bythe other one follows

Tesamorelin in one drawyour number, not a suggestion

mcg

Draw to

—units

enter an amount to calculate

Tesamorelin — what you set

—

Ipamorelin — comes with it

—

The ratio is fixed. This vial holds 2 parts Tesamorelin to 1 part Ipamorelin. That ratio was set when the vial was filled. No draw and no amount of water can change it.

Arithmetic, not a dose. This tool only divides the contents of a vial you already have. It does not recommend an amount, and no trial has tested this pair in people.

Open this vial in the full calculator

The vial and water are filled in. You enter the amount you want to check.

What goes wrong with this pair

Approved does not travel. Tesamorelin’s approval covers one use in one group of patients, and says nothing about pairing it with anything.
The Egrifta SV label describes a 2 mg vial mixed with sterile water, injected at once, and the rest thrown away. A 10 mg blend vial held for days matches nothing on that label.
Egrifta SV and Egrifta WR are stated by their own labels to be non-swappable. Strength, dose, mixing liquid and storage all differ.
Tesamorelin’s label already flags raised IGF-1 and rising blood sugar. Adding a second peptide that pushes the same hormone has never been measured.
In a blend vial the ratio is fixed by whoever mixed it, so the two amounts move together and cannot be set apart.

Common questions

What is the dose for tesamorelin and ipamorelin together?

There is no answer to give. No trial has set one, so any figure you find was written by a seller or a forum, and this site does not repeat those. What is on this page instead is what each peptide was separately given at, in the units the papers used, and the arithmetic for a vial you already hold.

Why does every other page have a schedule and this one does not?

Because those schedules have nothing behind them. A number repeated across a hundred pages is still one unsourced number. The searches above show what exists, and they take a second to re-run.

Does an absence of trials mean it is unsafe?

It means nobody knows. Absence of evidence is not evidence of harm, and it is not evidence of safety either. What can be said is narrower: nothing has measured what happens when these two go in together, so nobody can tell you what to watch for.

Can the two be mixed in one syringe?

That is a question about the chemistry of two powders in one liquid, and no published stability work covers this pair. Separately from that, a pre-mixed vial locks the ratio, so mixing removes a choice rather than adding one.

Is a blend vial the same as buying tesamorelin and ipamorelin separately?

No. Two vials keep the two amounts apart, and each one has its own calculator on this site. One blend vial ties them together at whatever ratio it was filled at. The table above shows what that costs you in control.

Is either one approved?

Tesamorelin is FDA-approved and has a printed label, for one narrow use that says nothing about pairing. Ipamorelin has no approved label at all. An approval covers a product, a use and a group of patients — it never covers a combination nobody applied for.

Keep reading

Every row above is read from the two records behind it. Each calculator opens on one compound’s own vial sizes, which is the sum to run when the two are bought separately.

Convert ipamorelin to units, beyond the Tesamorelin and ipamorelin blend

U-100, U-50 and U-40 barrels for ipamorelin, computed independently of Tesamorelin and ipamorelin.

Tesamorelin vial and water to a draw, separate from Tesamorelin and ipamorelin

Every step of the tesamorelin arithmetic printed, past Tesamorelin and ipamorelin.

All the combination pages, including Tesamorelin and ipamorelin

No page in the section prints a combined amount, including Tesamorelin and ipamorelin

The CJC-1295 and ipamorelin pair, beside Tesamorelin and ipamorelin

2 re-runnable searches behind CJC-1295 and ipamorelin, counted independently of Tesamorelin and ipamorelin.

Split Tesamorelin and ipamorelin with the ratio held fixed

What each peptide in a draw receives, printed rather than left to be worked out, including Tesamorelin and ipamorelin

Mixing math for one vial, not the Tesamorelin and ipamorelin blend

One calculator for every vial on this site, with Tesamorelin and ipamorelin as one example

The ipamorelin page behind Tesamorelin and ipamorelin

Ipamorelin has published human trial data, separate from Tesamorelin and ipamorelin.

Tesamorelin on its own, outside Tesamorelin and ipamorelin

An approved tesamorelin label exists — beyond Tesamorelin and ipamorelin.

Questions readers ask

Can I take Ipamorelin and tesamorelin together?

No trial has ever given the two to the same person. Searches of ClinicalTrials.gov and PubMed on 12 August 2026 found no study of the pair. The PubMed query returned six records, and not one of them gave both.

An absence of evidence is not a clearance. Tesamorelin is an approved medicine with a label, and that label covers one narrow use and says nothing about pairing it with anything.

What are the benefits of taking Ipamorelin and tesamorelin together?

None have been published, because nobody has run the pair. The nearest human test used two other molecules: eight healthy men given sermorelin and GHRP-2, alone and then together, as single injections into a vein.

Together they released more growth hormone than either one alone — and no more than the two separate results added up. The authors write that they could not show the two acting as a team.

How long should I take tesamorelin and Ipamorelin?

No study has published a course for the pair. Tesamorelin alone was studied for 26 weeks, with monitoring that does not translate into a self-directed schedule.

By week 26, IGF-1 was more than two standard deviations above normal in 47 of 100 people. HbA1c reached 6.5% or higher in 5 of 100, versus 1 of 100 on placebo. Ipamorelin’s two phase 2 human trials involved people recovering from bowel surgery and used intravenous dosing.

What's the best peptide to stack with tesamorelin?

No trial has compared one peptide stack with another. Without that comparison, a best-stack ranking would be invented.

One direction is on the page, though. Tesamorelin’s label already flags rising IGF-1 and rising blood sugar. Adding a second peptide that pushes the same hormone has never been measured.

5primary sources, each with the day we read it — open the documents used on this page